|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
ellipticine inhibits the reaction [AHR protein promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]] |
CTD |
PMID:11577022 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
ellipticine results in increased expression of BAX protein |
CTD |
PMID:16027529 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
ellipticine results in decreased expression of BCL2 protein |
CTD |
PMID:16027529 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
ellipticine results in decreased expression of and results in increased cleavage of BID protein |
CTD |
PMID:21843585 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
Acetylcysteine inhibits the reaction [ellipticine results in increased cleavage of and results in increased activity of CASP3 protein]; Butylated Hydroxyanisole inhibits the reaction [ellipticine results in increased cleavage of and results in increased activity of CASP3 protein]; ellipticine results in increased cleavage of and results in increased activity of CASP3 protein; pyrazolanthrone inhibits the reaction [ellipticine results in increased cleavage of and results in increased activity of CASP3 protein]; U 0126 inhibits the reaction [ellipticine results in increased cleavage of and results in increased activity of CASP3 protein] ellipticine results in increased activity of CASP3 protein |
CTD |
PMID:16027529 PMID:21843585 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
Acetylcysteine inhibits the reaction [ellipticine results in increased cleavage of and results in increased activity of CASP7 protein]; Butylated Hydroxyanisole inhibits the reaction [ellipticine results in increased cleavage of and results in increased activity of CASP7 protein]; ellipticine results in increased cleavage of and results in increased activity of CASP7 protein; pyrazolanthrone inhibits the reaction [ellipticine results in increased cleavage of and results in increased activity of CASP7 protein]; U 0126 inhibits the reaction [ellipticine results in increased cleavage of and results in increased activity of CASP7 protein] |
CTD |
PMID:21843585 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
ellipticine results in increased cleavage of and results in increased activity of CASP8 protein |
CTD |
PMID:21843585 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions |
ISO |
ellipticine results in increased activity of CASP9 protein ellipticine results in increased cleavage of and results in increased activity of CASP9 protein |
CTD |
PMID:16027529 PMID:21843585 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression increases expression |
ISO |
ellipticine results in decreased expression of CCNB1 protein ellipticine results in increased expression of CCNB1 protein |
CTD |
PMID:16027529 PMID:21843585 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
ellipticine results in decreased expression of CCND1 protein |
CTD |
PMID:21843585 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdc25c |
cell division cycle 25C |
decreases expression |
ISO |
ellipticine results in decreased expression of CDC25C protein |
CTD |
PMID:16027529 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions |
ISO |
ellipticine results in decreased expression of and results in increased phosphorylation of CDK1 protein |
CTD |
PMID:16027529 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
ellipticine results in increased expression of CDKN1A protein [ellipticine results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein; TP53 protein promotes the reaction [[ellipticine results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [ellipticine results in increased expression of CDKN1A protein] |
CTD |
PMID:29471073 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases expression |
ISO |
ellipticine results in decreased expression of CDKN1B protein |
CTD |
PMID:21843585 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases metabolic processing multiple interactions increases activity increases expression |
ISO EXP |
CYP1A1 protein results in increased metabolism of ellipticine [ellipticine results in decreased activity of CYP1A1 protein] inhibits the reaction [aristolochic acid I results in increased abundance of [7-(deoxyadenosin-N(6)-yl)aristolactam I co-treated with 7-(deoxyguanosin-N(2)-yl)aristolactam I co-treated with 7-(deoxyadenosin-N(6)--yl)aristolactam II]]; ellipticine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; ellipticine inhibits the reaction [troglitazone results in increased activity of CYP1A1 protein] ellipticine inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]; ellipticine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; TP53 protein promotes the reaction [ellipticine inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]]; TP53 protein promotes the reaction [ellipticine results in increased expression of CYP1A1 protein] [ellipticine results in decreased activity of CYP1A1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased abundance of Reactive Oxygen Species]; ellipticine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] ellipticine results in increased activity of CYP1A1 protein |
CTD |
PMID:17973980 PMID:18308446 PMID:18493746 PMID:21932800 PMID:22917556 PMID:29471073 More...
|
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases metabolic processing multiple interactions |
ISO EXP |
CYP1A2 protein results in increased metabolism of ellipticine ellipticine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein] |
CTD |
PMID:18493746 PMID:22917556 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases metabolic processing multiple interactions |
ISO |
CYP1B1 protein results in increased metabolism of ellipticine ellipticine inhibits the reaction [AHR protein promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]] |
CTD |
PMID:11577022 PMID:22917556 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
increases metabolic processing |
ISO |
CYP2C19 protein results in increased metabolism of ellipticine |
CTD |
PMID:22917556 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases metabolic processing |
ISO |
CYP2D6 protein mutant form results in increased metabolism of ellipticine |
CTD |
PMID:22917556 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases metabolic processing |
ISO |
CYP2E1 protein results in increased metabolism of ellipticine |
CTD |
PMID:22917556 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases metabolic processing |
ISO |
[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine]; Protons inhibits the reaction [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] CYP3A4 protein results in increased metabolism of ellipticine |
CTD |
PMID:22390216 PMID:22917556 PMID:30914192 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ftl1 |
ferritin light chain 1 |
multiple interactions |
ISO |
[ellipticine binds to FTL protein] which results in increased expression of H2AX protein modified form; FTL protein binds to and results in decreased uptake of ellipticine |
CTD |
PMID:30914192 |
|
NCBI chr 1:95,936,390...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725
|
|
G |
H2ax |
H2A.X variant histone |
increases expression multiple interactions |
ISO |
ellipticine results in increased expression of H2AX protein modified form [ellipticine binds to FTL protein] which results in increased expression of H2AX protein modified form |
CTD |
PMID:30914192 |
|
NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [ellipticine results in increased phosphorylation of MAPK1 protein]; Butylated Hydroxyanisole inhibits the reaction [ellipticine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:21843585 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [ellipticine results in increased phosphorylation of MAPK3 protein]; Butylated Hydroxyanisole inhibits the reaction [ellipticine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:21843585 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
decreases response to substance |
ISO |
MDM2 promoter SNP results in decreased susceptibility to ellipticine |
CTD |
PMID:17575151 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
ellipticine results in increased cleavage of PARP1 protein |
CTD |
PMID:21843585 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
ISO |
[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine |
CTD |
PMID:22390216 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Top2b |
DNA topoisomerase II beta |
decreases response to substance increases response to substance |
ISO |
TOP2B protein mutant form results in decreased susceptibility to ellipticine TOP2B protein mutant form results in increased susceptibility to ellipticine |
CTD |
PMID:15322234 PMID:16239602 |
|
NCBI chr15:9,051,661...9,111,220
Ensembl chr15:9,051,341...9,112,085
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases response to substance increases expression |
ISO |
TP53 protein promotes the reaction [[ellipticine results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [ellipticine inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]]; TP53 protein promotes the reaction [ellipticine results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [ellipticine results in increased expression of CYP1A1 protein] TP53 protein results in increased susceptibility to ellipticine ellipticine results in increased expression of TP53 protein |
CTD |
PMID:29471073 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression |
ISO |
ellipticine results in decreased expression of XIAP protein |
CTD |
PMID:16027529 PMID:21843585 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|